Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19

NCT05007496 is registered in ClinicalTrials.gov with Aivita Biomedical, Inc. as lead sponsor.

NCT NCT05007496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05007496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19
Lead sponsor
Aivita Biomedical, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 14, 2021
Completion date
May 31, 2021
Enrollment
145 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19